China Kidney Disease Network (CK-NET) 2015 Annual Data Report

Bai, Kunhao; Chen, Rui; Chu, Hong; Gan, Lanxia; Gao, Bixia; He, Xiangxiang; Liu, Lili; Long, Jianyan; Shi, Ying; Su, Zaiming; Sun, Xiaoyu; Tang, Wen; Wang, Fang; Wang, Haibo; Wang, Jinwei; Song, Weijie; Wang, Yue; Yang, Chao; Yu, Feng; Zhang, Dongliang; Zhang, Hong; Zhang, Luxia; Zhao, Ming‐Hui; Zhao, Xinju; Zheng, Lei; Zhou, Zhiye; Zuo, Li

doi:10.1016/j.kisu.2018.11.001

Cited by 102 publications

(101 citation statements)

References 23 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…If inconsistencies are detected, the entire daily data package of the hospital will be rejected and the hospital will be required to review and resubmit. 15 The Chinese Stroke Center Alliance (CSCA) database is a national, hospital-based, voluntary, multifaceted intervention and continuous quality improvement initiative that provides a unique platform to develop stroke centres, improve stroke care quality and clinical outcomes. The CSCA was designed and led by a team of volunteers from the China Stroke Association under the guidance of the National Center for Healthcare Quality Management in Neurological Diseases.…”

Section: Continuedmentioning

confidence: 99%

China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations

et al. 2020

View full text Add to dashboard Cite

China faces the greatest challenge from stroke in the world. The death rate for cerebrovascular diseases in China was 149.49 per 100 000, accounting for 1.57 million deaths in 2018. It ranked third among the leading causes of death behind malignant tumours and heart disease. The age-standardised prevalence and incidence of stroke in 2013 were 1114.8 per 100 000 population and 246.8 per 100 000 person-years, respectively. According to the Global Burden of Disease Study 2017, the years of life lost (YLLs) per 100 000 population for stroke increased by 14.6%; YLLs due to stroke rose from third highest among all causes in 1990 to the highest in 2017. The absolute numbers and rates per 100 000 population for all-age disability-adjusted life years (DALYs) for stroke increased substantially between 1990 and 2017, and stroke was the leading cause of all-age DALYs in 2017. The main contributors to cerebrovascular diseases include behavioural risk factors (smoking and alcohol use) and pre-existing conditions (hypertension, diabetes mellitus, dyslipidaemia and atrial fibrillation (AF)). The most prevalent risk factors among stroke survivors were hypertension (63.0%-84.2%) and smoking (31.7%-47.6%). The least prevalent was AF (2.7%-7.4%). The prevalences for major risk factors for stroke are high and most have increased over time. Based on the latest national epidemiological data, 26.6% of adults aged ≥15 years (307.6 million adults) smoked tobacco products. For those aged ≥18 years, age-adjusted prevalence of hypertension was 25.2%; adjusted prevalence of hypercholesterolaemia was 5.8%; and the standardised prevalence of diabetes was 10.9%. For those aged ≥40 years, the standardised prevalence of AF was 2.31%. Data from the Hospital Quality Monitoring System showed that 3 010 204 inpatients with stroke were admitted to 1853 tertiary care hospitals during 2018. Of those, 2 466 785 (81.9%) were ischaemic strokes (ISs); 447 609 (14.9%) were intracerebral haemorrhages (ICHs); and 95 810 (3.2%) were subarachnoid haemorrhages (SAHs). The average age of patients admitted was 66 years old, and nearly 60% were male. A total of 1555 (0.1%), 2774 (0.6%) and 1347 (1.4%) paediatric strokes (age <18 years) were identified among IS, ICH and SAH, respectively. Over one-third (1 063 892 (35.3%)) of the patients were covered by urban resident basic medical insurance, followed by urban employee basic medical insurance (699 513 (23.2%)) and new rural cooperative medical schema (489 361 (16.3%)). The leading risk factor was hypertension (67.4% for IS, 77.2% for ICH and 49.1% for SAH), and the leading comorbidity was pneumonia or pulmonary infection (10.1% for IS, 31.4% for ICH and 25.2% for SAH). In-hospital death/discharge against medical advice rate was 8.3% for stroke inpatients, ranging from 5.8% for IS to 19.5% for ICH. The median and IQR of length of stay was 10.0 (7.0–14.0) days, ranging from 10.0 (7.0–13.0) in IS to 14.0 (8.0–22.0) in SAH. Data from the Chinese Stroke Center Alliance demonstrated that the composite scores of guideline-recommended key performance indicators for patients with IS, ICH and SAH were 0.77±0.21, 0.72±0.28 and 0.59±0.32, respectively.

show abstract

Section: Continuedmentioning

confidence: 99%

China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients undergoing maintenance hemodialysis (MHD) have abnormal immune systems because of the uremic state, 6 which is often accompanied by significant comorbidities like cardiovascular disease, diabetes, and cerebrovascular disease. 7,8 It would be interesting to know whether the clinical course of patients undergoing MHD having COVID-19 is different from that of other COVID-19 patients. Moreover, patients undergoing MHD in outpatient department must routinely visit the hospital and stay with dozens of patients undergoing MHD in a dialysis unit for 3-4 hours at a time, which may lead to widespread crosscontamination.…”

mentioning

confidence: 99%

Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China

Xiong

Tang

Liu

et al. 2020

JASN

251

284

View full text Add to dashboard Cite

BackgroundReports indicate that those most vulnerable to developing severe coronavirus disease 2019 (COVID-19) are older adults and those with underlying illnesses, such as diabetes mellitus, hypertension, or cardiovascular disease, which are common comorbidities among patients undergoing maintenance hemodialysis. However, there is limited information about the clinical characteristics of hemodialysis patients with COVID-19 or about interventions to control COVID-19 in hemodialysis centers.MethodsWe collected data retrospectively through an online registration system that includes all patients receiving maintenance hemodialysis at 65 centers in Wuhan, China. We reviewed epidemiologic and clinical data of patients with laboratory-confirmed COVID-19 between January 1, 2020 and March 10, 2020.ResultsOf 7154 patients undergoing hemodialysis, 154 had laboratory-confirmed COVID-19. The mean age of the 131 patients in our analysis was 63.2 years; 57.3% were men. Many had underlying comorbidities, with cardiovascular disease (including hypertension) being the most common (68.7%). Only 51.9% of patients manifested fever; 21.4% of infected patients were asymptomatic. The most common finding on chest computed tomography (CT) was ground-grass or patchy opacity (82.1%). After initiating comprehensive interventions—including entrance screening of body temperature and symptoms, universal chest CT and blood tests, and other measures—new patients presenting with COVID-19 peaked at 10 per day on January 30, decreasing to 4 per day on February 11. No new cases occurred between February 26 and March 10, 2020.ConclusionsWe found that patients receiving maintenance hemodialysis were susceptible to COVID-19 and that hemodialysis centers were high-risk settings during the epidemic. Increasing prevention efforts, instituting universal screening, and isolating patients with COVID-19 and directing them to designated hemodialysis centers were effective in preventing the spread of COVID-19 in hemodialysis centers.

show abstract

“…A recent study analyzed the change in burden of CKD globally from 1990 to 2016 by using the Global Burden of Disease study data, the results showed that the incidence of CKD increased by 89%, prevalence increased by 87%, death due to CKD increased by 98% [3]. According to the data of a national epidemiological survey, it was estimated that the number of CKD patients in China was more than 100 million [6], and the number of patients receiving renal replacement therapy has increased rapidly in recent years [7]. There were about 553000 people received the hemodialysis and 55000 patients underwent peritoneal dialysis in 2015 [7].…”

Section: Introductionmentioning

confidence: 99%

“…According to the data of a national epidemiological survey, it was estimated that the number of CKD patients in China was more than 100 million [6], and the number of patients receiving renal replacement therapy has increased rapidly in recent years [7]. There were about 553000 people received the hemodialysis and 55000 patients underwent peritoneal dialysis in 2015 [7]. It was estimated that the prevalence of CKD and end-stage renal disease (ESRD) would increase rapidly in the future [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The rs1058587 of growth differentiation factor 15 increased the development and mortality risk of end-stage renal disease

Shen

CHEN

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Growth differentiation factor 15 (GDF-15) is a member of transforming growth factor β (TGF- β). Recent studies have shown that the serum level of GDF-15 increased and was associated with the occurrence and progression of the many diseases. However, the effect of GDF15 variants on end-stage renal disease (ESRD) is still unclear. The study was to explore the effect of GDF15 rs 1058587 on the susceptibility to ESRD and mortality risk of ESRD. Methods A total of 296 ESRD patients and 300 healthy individuals were enrolled. All the patients were followed-up for 3 years. The genotype of GDF-15 rs 1058587 was determined PCR amplification and Sanger sequencing. The baseline serum GDF-15 level was measured by enzyme-linked immunosorbent assay (ELISA). Results The frequency of G gene in ESRD patients was higher in ESRD patients than in controls (30.14% vs. 25.17%, P =0.027). The patients with CG/GG genotype had higher mortality risk in the dominant model (CG+GG vs. CC, OR= 1.708, 95% CI: 1.288 - 2.461, P = 1.00×10 -3 ). Multivariate analysis showed that age > 60 years, total cholesterol > 6 mmol/L, and genotype GG were independent risk factors for mortality in patients with ESRD (P <0.05), and survival analysis informed us that the three-year overall survival of patients with GG genotype was significantly lower than other genotype patients. Conclusions The G allele or CG/GG genotype of GDF15 was associated with higher susceptible risk of ESRD and the genotype GG was an independent risk factor for overall mortality in patients with ESRD.

show abstract

China Kidney Disease Network (CK-NET) 2015 Annual Data Report

Cited by 102 publications

References 23 publications

Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China

The rs1058587 of growth differentiation factor 15 increased the development and mortality risk of end-stage renal disease

Contact Info

Product

Resources

About